Cancer-fighting startup Accession Therapeutics has raised £16.6 million to advance its two lead preclinical programmes to clinical trials. The Oxford company is developing novel immuno-oncology therapeutics combining high specificity and potency with the ability to counter tumour diversity. New investors, including the Singaporean fund iGlobe Partners, join Primavera Venture Partners, Birk Venture and biotech angels … Continue reading £16.6m raised by cancer-fighting startup Accession Therapeutics